MaxCyte and Ori Biotech Announce Collaboration to Enhance Cell Therapy Manufacturing

MaxCyte, Inc. and Ori Biotech Ltd. have entered a strategic collaboration to enhance the efficiency, scalability, and productivity of cell therapy manufacturing by integrating MaxCyte’s ExPERT platform and Flow Electroporation technology with Ori’s IRO manufacturing platform. This partnership aims to optimize yield and streamline manufacturing timelines for gene-edited T cells, initially focusing on CD19 CAR expression via CRISPR knock-in in activated T cells. MaxCyte’s technology, which is currently used in over 19 active clinical and commercial programs, offers high-efficiency transfection at clinical scale, while Ori’s platform provides automated fluid handling, customizable mixing, and a tubeless sterile connection system to improve cell culture efficiency. The collaboration seeks to address critical manufacturing challenges and accelerate the path from research to commercialization of cell therapies, enabling broader patient access to next-generation treatments. Both companies emphasize their commitment to developing scalable and flexible solutions that enhance the commercial viability of cell and gene therapies. This integrated approach is expected to significantly improve the production process for autologous cellular therapies, reducing bottlenecks and increasing clinical output.